SHR 7367
Alternative Names: SHR-7367Latest Information Update: 23 May 2023
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antineoplastics
- Mechanism of Action CD40 antigen modulators; Tumor associated antigen expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 Mar 2023 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease) in China (unspecified route) (NCT05740202)
- 13 Feb 2023 Preclinical trials in Solid tumours in China (unspecified route) (Prior to February 2023)
- 13 Feb 2023 Shanghai Hengrui Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in February 2023 (NCT05740202)